Tech Company Financing Transactions

Seragon Pharmaceuticals Funding Round

Seragon Pharmaceuticals closed a $30 million Series A funding round on 10/18/2013. Backers included Aisling Capital, OrbiMed and The Column Group.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
This financing provides Seragon with the resources to advance our pipeline, including ARN-810 which is currently being evaluated in a Phase I trial for ER+ metastatic breast cancer.

Company Information

Company Status
Acquired or Merged
Mailing Address
12780 El Camino Real 302
San Diego, CA 92130
Email Address
Seragon Pharmaceuticals is developing small-molecule drugs for the treatment of estrogen receptor dependent breast cancer.
Seragon Pharmaceuticals LinkedIn Company Profile
Social Media
Seragon Pharmaceuticals Company Twitter Account
Company News
Seragon Pharmaceuticals News
Seragon Pharmaceuticals on Facebook
Seragon Pharmaceuticals on YouTube

Management Team

Email & Social
Chief Executive Officer
Richard Heyman
  Richard Heyman LinkedIn Profile  Richard Heyman Twitter Account  Richard Heyman News  Richard Heyman on Facebook
Chief Financial Officer
Patricia Millican
  Patricia Millican LinkedIn Profile  Patricia Millican Twitter Account  Patricia Millican News  Patricia Millican on Facebook
Vice President
Nicholas Smith
  Nicholas Smith LinkedIn Profile  Nicholas Smith Twitter Account  Nicholas Smith News  Nicholas Smith on Facebook



Browse more venture capital transactions:

Prev: 10/18/2013: Usermind venture capital transaction
Next: 10/18/2013: venture capital transaction


Share this article


Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary